Infant Bacterial Therapeutics AB (publ) (IBT-B) - Total Liabilities

Latest as of September 2025: Skr53.87 Million SEK ≈ $5.80 Million USD

Based on the latest financial reports, Infant Bacterial Therapeutics AB (publ) (IBT-B) has total liabilities worth Skr53.87 Million SEK (≈ $5.80 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore IBT-B operating cash flow to assess how effectively this company generates cash.

Infant Bacterial Therapeutics AB (publ) - Total Liabilities Trend (2013–2024)

This chart illustrates how Infant Bacterial Therapeutics AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Check IBT-B asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Infant Bacterial Therapeutics AB (publ) Competitors by Total Liabilities

The table below lists competitors of Infant Bacterial Therapeutics AB (publ) ranked by their total liabilities.

Company	Country	Total Liabilities
QPM Energy Ltd AU:QPM	Australia	AU$170.18 Million
Billion Electric Co Ltd TW:3027	Taiwan	NT$552.80 Million
Inovio Pharmaceuticals Inc NASDAQ:INO	USA	$77.11 Million
United Polyfab Gujarat Limited NSE:UNITEDPOLY	India	Rs1.49 Billion
Apollo Power Ltd TA:APLP	Israel	ILA91.02 Million
Yusin Holding Corp TW:4557	Taiwan	NT$2.05 Billion
Hotel Holiday Garden TW:2702	Taiwan	NT$3.37 Billion
District Metals Corp V:DMX	Canada	CA$273.08K

Liability Composition Analysis (2013–2024)

This chart breaks down Infant Bacterial Therapeutics AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see IBT-B company net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	3.15	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.43	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.30	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Infant Bacterial Therapeutics AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Infant Bacterial Therapeutics AB (publ) (2013–2024)

The table below shows the annual total liabilities of Infant Bacterial Therapeutics AB (publ) from 2013 to 2024.

Year	Total Liabilities	Change
2024-12-31	Skr69.30 Million ≈ $7.46 Million	+50.07%
2023-12-31	Skr46.18 Million ≈ $4.97 Million	+157.80%
2022-12-31	Skr17.91 Million ≈ $1.93 Million	+35.46%
2021-12-31	Skr13.22 Million ≈ $1.42 Million	+30.11%
2020-12-31	Skr10.16 Million ≈ $1.09 Million	+29.05%
2019-12-31	Skr7.88 Million ≈ $847.58K	+18.36%
2018-12-31	Skr6.65 Million ≈ $716.08K	+0.02%
2017-12-31	Skr6.65 Million ≈ $715.97K	+36.25%
2016-12-31	Skr4.88 Million ≈ $525.49K	-36.86%
2015-12-31	Skr7.73 Million ≈ $832.30K	+120.59%
2014-12-31	Skr3.51 Million ≈ $377.30K	+1356.61%
2013-12-31	Skr240.70K ≈ $25.90K	--

About Infant Bacterial Therapeutics AB (publ)

ST:IBT-B Sweden Biotechnology

Market Cap

$75.51 Million

Skr701.68 Million SEK

Market Cap Rank

#20275 Global

#360 in Sweden

Share Price

Skr53.90

Change (1 day)

-3.75%

52-Week Range

Skr43.45 - Skr81.50

All Time High

Skr266.00